-
US Justice Dept releasing new batch of Epstein files
-
South Africa and Israel expel envoys in deepening feud
-
French eyewear maker in spotlight after presidential showing
-
Olympic dream 'not over', Vonn says after crash
-
Brazil's Lula discharged after cataract surgery
-
US Senate races to limit shutdown fallout as Trump-backed deal stalls
-
'He probably would've survived': Iran targeting hospitals in crackdown
-
Djokovic stuns Sinner to set up Australian Open final with Alcaraz
-
Mateta omitted from Palace squad to face Forest
-
Gold, silver prices tumble as investors soothed by Trump's Fed pick
-
Trump attorney general orders arrest of ex-CNN anchor covering protests
-
Djokovic 'pushed to the limit' in stunning late-night Sinner upset
-
Tunisia's famed blue-and-white village threatened after record rains
-
Top EU official voices 'shock' at Minneapolis violence
-
Kremlin says agreed to halt strikes on Kyiv until Sunday
-
Carrick calls for calm after flying start to Man Utd reign
-
Djokovic to meet Alcaraz in Melbourne final after five-set marathon
-
Italian officials to testify in trial over deadly migrant shipwreck
-
Iran says defence capabilities 'never' up for negotiation
-
UN appeals for more support for flood-hit Mozambicans
-
Lijnders urges Man City to pile pressure on Arsenal in title race
-
Fulham sign Man City winger Oscar Bobb
-
Strasbourg's Argentine striker Panichelli sets sights on PSG, World Cup
-
Jesus 'made love': Colombian president irks Christians with steamy claim
-
IAEA board meets over Ukraine nuclear safety concerns
-
Eurozone growth beats 2025 forecasts despite Trump woes
-
Israel to partially reopen Gaza's Rafah crossing on Sunday
-
Dutch PM-elect Jetten says not yet time to talk to Putin
-
Social media fuels surge in UK men seeking testosterone jabs
-
Forest face Fenerbahce, Celtic draw Stuttgart in Europa League play-offs
-
US speed queen Vonn crashes at Crans-Montana, one week before Olympics
-
Trump nominates former US Fed official as next central bank chief
-
Alcaraz defends controversial timeout after beaten Zverev fumes
-
New Dutch government pledges ongoing Ukraine support
-
Newcastle still coping with fallout from Isak exit, says Howe
-
Chad, France eye economic cooperation as they reset strained ties
-
Real Madrid to play Benfica, PSG face Monaco in Champions League play-offs
-
Everton winger Grealish set to miss rest of season in World Cup blow
-
Trump brands Minneapolis nurse killed by federal agents an 'agitator'
-
Arteta focuses on the positives despite Arsenal stumble
-
Fijian Drua sign France international back Vakatawa
-
Kevin Warsh, a former Fed 'hawk' now in tune with Trump
-
Zverev rails at Alcaraz timeout in 'one of the best battles ever'
-
Turkey leads Iran diplomatic push as Trump softens strike threat
-
Zelensky backs energy ceasefire, Russia bombs Ukraine despite Trump intervention
-
'Superman' Li Ka-shing, Hong Kong billionaire behind Panama ports deal
-
Skiing great Lindsey Vonn crashes at Crans-Montana, one week before Olympics
-
Slot warns Liverpool 'can't afford mistakes' in top-four scrap
-
Paris show by late Martin Parr views his photos through political lens
-
'Believing' Alcaraz outlasts Zverev in epic to reach maiden Melbourne final
| RBGPF | 1.65% | 83.78 | $ | |
| SCS | 0.12% | 16.14 | $ | |
| RYCEF | -2.69% | 16 | $ | |
| NGG | -0.33% | 84.77 | $ | |
| CMSC | -0.02% | 23.69 | $ | |
| AZN | 0.38% | 92.94 | $ | |
| GSK | 1.03% | 51.18 | $ | |
| BP | 0.09% | 38.075 | $ | |
| BTI | -0.47% | 59.93 | $ | |
| RIO | -3.08% | 92.29 | $ | |
| VOD | -0.55% | 14.63 | $ | |
| BCE | 0.1% | 25.51 | $ | |
| JRI | 0.23% | 12.985 | $ | |
| BCC | -1.31% | 79.132 | $ | |
| RELX | -1.25% | 35.72 | $ | |
| CMSD | 0.05% | 24.073 | $ |
Ghostwriters, polo shirts, and the fall of a landmark pesticide study
A flagship study that declared the weedkiller Roundup posed no serious health risks has been retracted with little fanfare, ending a 25-year saga that exposed how corporate interests can distort scientific research and influence government decision-making.
Published in Regulatory Toxicology and Pharmacology in 2000, the paper ranks in the top 0.1 percent of citations among studies on glyphosate -- the key ingredient in Roundup, owned by agri-giant Monsanto and at the center of cancer lawsuits worth billions of dollars.
In his retraction note last week, the journal's editor-in-chief, Martin van den Berg, cited a litany of serious flaws from failing to include carcinogenicity studies available at the time to undisclosed contributions by Monsanto employees and even questions around financial compensation.
Elsevier, the journal's Dutch publisher, told AFP in a statement that it upholds the "highest standards of rigor and ethics" and that "as soon as the current editor became aware of concerns regarding this paper a matter of months ago, due process began."
But it did not address the fact that concerns date back to 2002, when critics wrote to Elsevier about "conflicts of interest, lack of transparency, and the absence of editorial independence" at the journal, including specific worries about Monsanto.
The matter exploded into public view in 2017, when internal corporate documents released during litigation showed one of Monsanto's own scientists admitting to "ghostwriting."
Harvard University science historian Naomi Oreskes, who co-authored a paper this September detailing the extent of the "fraud" in the 2000 study, told AFP that while she was "very gratified" at the "long overdue" action, but warned that "the scientific community needs better mechanisms to identify and retract fraudulent papers."
"This is completely in alignment with what we were calling them out for at the time," Lynn Goldman, a pediatrician and epidemiologist at GWU who co-signed the 2002 letter, added to AFP.
- Polo shirts -
Two of the paper's three original authors have since died, while first author Gary Williams, a professor at New York Medical College, did not respond to AFP's request for comment.
Monsanto maintains it acted appropriately, and that its product is safe. "Monsanto's involvement with the Williams et al paper did not rise to the level of authorship and was appropriately disclosed in the acknowledgments."
The company declined to comment on internal emails that suggested otherwise, including one in which a Monsanto scientist asked a colleague whether "the team of people" who worked on the Williams paper and another study "could receive Roundup polo shorts as a token of appreciation for a job well done."
Glyphosate was brought to market as a herbicide in the 1970s and initially welcomed as less toxic than DDT.
But its soaring use -- especially after Monsanto introduced glyphosate-tolerant seeds that allowed it to be sprayed widely over crops -- drew increasing scrutiny in the 1990s, making the 2000 paper hugely influential.
According to Oreskes's research, it was cited as supporting evidence for glyphosate's safety by groups ranging from the Canadian Forest Service to the International Court of Justice, the US Congress and the European Parliamentary Research Service.
- Legal interest -
In 2015, the World Health Organization's International Agency for Research on Cancer classified glyphosate as "probably carcinogenic to humans."
Several countries have since moved to restrict or ban its use, including France, which has prohibited household applications. Bayer, which acquired Monsanto, said it would phase out Roundup for US residential use in 2023 in response to growing lawsuits.
Nathan Donley, a scientist with the Center for Biological Diversity, told AFP he does not expect the retraction to sway the US Environmental Protection Agency, now under the pro-agricultural-industry Donald Trump administration, which has thrown its weight behind Bayer in an ongoing Supreme Court case.
But "it could play a role in litigation that is moving forward in the US against the EPA's proposed decision to renew glyphosate," Donley told AFP, adding that European regulators might also take note.
For Donley and others, the deeper concern is that the case may be far from unique.
"I am sure there (are a) lot (of) such ghost-written and undeclared conflict papers in the literature, but they are very difficult to unearth unless one goes really deep in litigation cases," John Ioannidis, a Stanford University professor who founded the field of meta-research told AFP.
R.Chavez--AT